Welcome to our dedicated page for Sensus Healthcare news (Ticker: SRTS), a resource for investors and traders seeking the latest updates and insights on Sensus Healthcare stock.
Sensus Healthcare, Inc. reports developments tied to its medical-device business for superficial radiotherapy treatments for oncological and non-oncological skin conditions. The company’s updates center on SRT and IG-SRT technology, including systems used in the treatment of non-melanoma skin cancer and keloids, as well as products and services that support dermatology and radiation-oncology practices.
Recurring news topics include quarterly results, reimbursement and CPT coding for superficial radiotherapy, customer acquisition programs, financing options through Sensus Healthcare Financial Services, installed-base software such as Sensus Link, Fair Deal Agreement activity, international customer development, and commercial or legal matters related to product sales and deployments.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
On April 25, 2023, Sensus Healthcare, Inc. (SRTS) announced a conference call scheduled for May 3, 2023, at 4:30 PM ET to discuss first-quarter 2023 financial results. During this call, management will also provide a business update and discuss ongoing and upcoming milestones. Participants can pre-register for the call to receive a unique dial-in number, allowing them to bypass the operator. The live webcast will be accessible through the company’s website, with a replay available until June 3, 2023. Sensus Healthcare specializes in non-invasive treatments for oncological and non-oncological conditions, offering innovative devices for skin cancer and aesthetic procedures.
Sensus Healthcare (Nasdaq:SRTS) has launched Sensus Cloud, a groundbreaking cloud-based platform designed for asset and EMR management in healthcare. This platform allows healthcare providers to collect real-time data from medical devices, streamlining patient monitoring and treatment management.
Key features include an intuitive interface for tracking patient treatment history, device usage, and service details, alongside predictive analytics for proactive care management. The system ensures data security with multi-factor authentication and encryption, enhancing user and patient data protection. Sensus Healthcare will showcase this innovative platform at the American Academy of Dermatology Annual Meeting from March 17-19, 2023.
Sensus Healthcare reported a 65% increase in full-year revenues, totaling $44.5 million for 2022, driven by increased product demand. Fourth-quarter revenues reached $13.1 million, slightly up from $13.0 million year-over-year. However, net income fell to $2.8 million ($0.17 per share) compared to $5.3 million ($0.32 per share) in Q4 2021, largely due to rising manufacturing costs.
The company ended 2022 with $25.5 million in cash and no debt, with expectations of continued growth and a focus on expanding aesthetic product offerings in 2023.